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Background: Discontinuation of antipsychotic treatment for schizophrenia can interrupt improvement and
exacerbate the illness. Reasons for discontinuing treatment are multifactorial and include adherence, efficacy and
tolerability issues. Poor adherence may be addressed through non-pharmacological approaches as well as through
pharmacological ones, ie ensured delivery of medication, such as that achieved with long-acting injectable (LAI)
antipsychotics. However, attitudes of healthcare professionals (HCPs) towards LAI antipsychotics may influence their
prescribing decisions and may influence medication choices offered to patients. We therefore conducted a survey
to investigate factors driving LAI use as well as physician and nurse attitudes to LAI antipsychotics and to different
injection sites.
Methods: An independent market research agency conducted the survey of HCPs across Europe. Participants were
recruited by telephone and completed the survey online. Using conjoint analyses (a multivariate statistical
technique analysing preferences on the basis of ranking a limited number of attributes which are presented
repetitively), attitudes to oral versus LAI medication and gluteal versus deltoid injection routes were assessed.
Results: A total of 891 HCPs across Europe were surveyed. Of these, 40% would choose LAI antipsychotics for first
episode patients whereas 90% would select LAI antipsychotics for chronic patients with two to five psychotic
episodes. Dominant elements in antipsychotic choice were low sedation but no tardive dyskinesia, no or mild pain
at injection and low risk of embarrassment or impact upon therapeutic alliance. Eighty-six per cent of respondents
considered that having the choice of a deltoid as well as gluteal administration site was beneficial over not having
that choice. Two thirds of respondents said they agreed that medication administration via the deltoid muscle may
reduce social embarrassment associated with LAI antipsychotics and most respondents (61%) believed that
administration of LAI antipsychotics into the deltoid muscle as opposed to the gluteal muscle may be more
respectful to the patient.
Conclusions: In this survey of physicians and nurses, attitudes towards LAI antipsychotics compared with oral
medication were generally positive. Respondents considered that the availability of a deltoid administration route
would offer increased choice in LAI antipsychotic administration and may be perceived as more respectful and less
socially embarrassing.
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Treatment continuation is a pervasive challenge in
schizophrenia management [1]. Factors leading to treat-
ment discontinuation include inability to adhere to
medication regimens, lack of efficacy and tolerability
issues [2-4]. Treatment discontinuation can lead to
increased relapse rates [5,6] and poorer long-term
outcomes [6]. With each successive relapse, chronicity is
increased and response to treatment is reduced [7]. En-
suring treatment continuation through improved adher-
ence is therefore a major objective in the treatment of
schizophrenia and can impact on morbidity [6,8-11],
attempted suicide [6,12], severity of violent behaviour
[13], and patient satisfaction [9] as well as direct and in-
direct healthcare costs [14-16].
Long-acting injectable (LAI) antipsychotics are amongst
the pharmacological options available to address ad-
herence problems in patients. LAI antipsychotics offer
a number of benefits compared with oral medication,
including transparency of adherence [17], allowing
healthcare professionals (HCPs) to be alerted and to
intervene appropriately if patients fail to take their
medication [18]. Other benefits of LAI antipsychotics
include a reliable drug delivery with reduced peak–
trough plasma levels [19], improved patient outcomes
[20], improved patient and physician satisfaction [21]
and lower relapse rates [22-24] than oral therapy. Fur-
thermore, with LAI antipsychotics, there is regular
contact between the patient and treatment team [25].
Several first-generation LAI antipsychotics and three
second-generation LAI antipsychotics are currently
available for administration into the gluteal muscle.
Risperidone long-acting injectable (RLAI) is an aqueous-
based, second-generation antipsychotic, available world-
wide for both gluteal and deltoid injection [26]. The
deltoid administration of RLAI has been shown to
be bioequivalent to the gluteal administration [27].
Olanzapine pamoate, a prolonged-release suspension of
olanzapine, is also available for gluteal injection [28]. A
third atypical long-acting antipsychotic, paliperidone
palmitate is available in the USA and Europe for injection
in either the gluteal or deltoid muscle [29,30]. These new
formulations provide patients and physicians with a choice
of administration site for LAI antipsychotics.
Despite the adherence benefits of LAI antipsychotics,
there is still considerable resistance to their first-line usage
[31-33]. In one study directly comparing attitudes of
psychiatrists, patients and relatives, patients were more
negative towards long-acting or depot formulations than
psychiatrists and relatives [32]. Experience of injectable
antipsychotics can positively influence attitudes towards
treatment, with up to 47% of patients experienced with
this type of formulation favouring LAI antipsychotics over
oral medication [33-35]. However, patients are often notinformed of long-acting or depot formulations by their
psychiatrist [32] and the attitudes of HCPs towards LAI
medication may limit treatment choices offered to patients
[36]. Educating staff, patients and families can help ad-
dress prejudice and stigma towards LAI antipsychotics,
increase familiarity and ultimately increase preference for
this type of medication [37].
At the time of our study, studies investigating influen-
cing factors and perceived preferences for antipsychotics
were lacking. Attributes that may influence prescribing
of long-acting formulations and patient acceptance in-
clude stigma [32], pain associated with injection [19]
and embarrassment arising from the need to remove
clothing for gluteal injections [25]. Although first-
generation depot antipsychotics that use oil-based
formulations are associated with pain on injection [19],
aqueous-based formulations of LAI antipsychotics gen-
erally have good injection site tolerability [19]. Further-
more, injection into the deltoid muscle requires minimal
removal of clothing [38]. A study reporting the findings
from a Medication Preference Questionnaire for Patients
cited the most common reasons for preferring the del-
toid site (expressed by >25% of patients) as easier, less
embarrassing, faster, or less painful than injection in the
gluteal site [39]. The availability of both deltoid and glu-
teal formulations of LAI medication could therefore fa-
cilitate patient acceptance and long-term adherence to
injectable antipsychotic medication. The objective of this
present survey was to understand factors driving LAI
use, as well as attitudes and preferences for different ad-
ministration sites, both in comparison with oral medica-
tion and with other LAI medication. The survey used
conjoint analysis, consisting of a series of trade-off
questions. Participants were asked to choose between
‘bundles’ of defined attributes. This method permits the
determination of dominant attribute levels from repeti-
tive choice preferences [40].
Methods
Participants
The purpose of the present study was to understand
physician and nurse attitudes and preferences for differ-
ent administration sites of antipsychotic medication. An
independent market research agency, funded by Janssen,
conducted a survey of HCPs, including both physicians
and nurses from across Europe, between November
2007 and January 2008. Participants were selected on
two criteria: activity in the relevant clinical field, ie
treating patients with schizophrenia, and willingness to
participate in the study. They were recruited by tele-
phone and asked to complete an online, choice-based
survey to determine the relative importance of oral ver-
sus long-acting attributes on attitudes to antipsychotic
use. The surveys were completed anonymously and
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Individual patient information was not collected and Insti-
tutional Review Board (IRB) review was not required.
Participants were offered a small financial incentive of
50–70 Euros, depending on their country of origin, which
they could nominate to donate to charity. Completed
surveys were returned directly and blinded to the inde-
pendent agency for data analysis.
Data collection
The survey used choice-based conjoint analysis to gain
insight into physician and nurse attitudes to the admin-
istration of long-acting antipsychotics. Conjoint analysis
originated in mathematical psychology and was first
introduced in marketing research. Nowadays, it is widely
used in healthcare for eliciting patients’ and the community's
preferences in the delivery of health services; establishing
consultants’ preferences in priority setting; developing out-
come measures; determining optimal treatments for patients;
evaluating alternatives within randomized controlled trials;
and establishing patients’ preferences in the doctor–patient
relationship [40].
Antipsychotic treatment characteristics
The characteristics of the antipsychotic treatment options
included in this study are indicated below. Characteristics
were chosen to elicit preferences for oral versus LAI anti-
psychotic medication (see subsection Choice-based con-
joint exercise 1 - oral versus long-acting decisions) and
deltoid versus gluteal administration (see subsection
Choice-based conjoint exercise 2 - long-acting pre-
scription decisions). Characteristics were derived from
results previously published in the literature including
findings from Medication Preference Questionnaires
[16,22,29,32] and expert opinion obtained in advisory




2. Frequency of administration
■ once a day
3. Level of fluctuation of active compound in the blood
plasma
■ high4. Frequency of healthcare staff contact with patient
■ depends on level of care




1. Formulation■ buttock muscle injection (gluteal)
■ deltoid muscle injection
2. Frequency of administration
■ once every 2 weeks
■ once every 3 weeks
■ once every 4 weeks




4. Frequency of healthcare staff contact with patient
■ fixed: once per 2 weeks
■ fixed: once per 3 weeks
■ fixed: once per 4 weeks
5. Degree of certainty of assessing adherence with
medication
■ high
Choice-based conjoint exercise 2 – long-acting prescription
decisions
1. Routes of administration■ gluteal muscle injection (buttock)
■ deltoid muscle injection
2. Dose scheme
■ once every 2 weeks
■ once every 3 weeks
■ once every 4 weeks
3. A significant degree of side effects
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■ sedation
■ metabolic side effects (diabetes,
hypercholesterolaemia, dyslipidaemia)
■ sexual side effects (prolactin)
■ extrapyramidal side effects
■ tardive dyskinesia





5. Storage & transport
■ cold chain
■ no cold chain storage
6. Onset of action
■ within days
■ within weeks
7. Method of administration
■ injection technique with high risk of
embarrassment & potential harm to therapeutic
relationship
■ injection technique with low risk of
embarrassment & potential harm to therapeutic
relationship
8. Needle length







Assumptions underlying conjoint analysis
Conjoint analysis requires respondents to rate or rank a
limited number of attributes related to antipsychotic
features and make repetitive trade-offs between these
attributes in order to reveal the relative importance of
aspects of antipsychotic treatment [35]. The analysis
assumes that each treatment option can be broken down
into specific characteristics, and that each characteristicis defined by a number of levels. Levels refer to the
range of plausible estimates for each characteristic. For
example, the levels for the characteristic ‘pain at injec-
tion site’ might be absent, mild, moderate and severe
depending on the specific treatment. The second as-
sumption is that respondents have unique utilities for
each attribute level. In this context, ‘utility’ is a number
that represents the respondent’s preference for a particu-
lar characteristic, with higher utilities indicating greater
preference and features most likely to drive treatment
decisions. The utility scores represent the relative
preference respondents have for the different levels
within that specific attribute and can therefore only be
compared within that attribute. For example, one can
compare the scores of absent and mild pain within ‘pain
at injection site’, but not between ‘mild pain at injection
site’ and ‘side effect sedation’ as these are levels within
different attributes. Within an attribute (eg pain at injec-
tion site), the least preferred level (severe pain) is always
zero for the ease of understanding. The final assumption
is that utilities can be combined across attributes. For
example, if the sum of a patient’s utilities for the
attributes of treatment A is greater than the sum of util-
ities for the attributes of treatment B, the patient should
prefer treatment A to treatment B.
Conjoint analysis questionnaire
The choice-based conjoint task consisted of two groups
of questions. Firstly, HCPs rated attributes relating to
oral versus long-acting medications and secondly rated
one long-acting medication versus another long-acting
medication with varying attributes, such as dose interval,
administration site and pain at injection site. Scenarios
that described all possible configurations given the
attributes and levels were included; an example of such
a scenario is shown in Figure 1. The experimental design
was optimized in such a way that all combinations of at-
tribute levels were shown an approximately equal num-
ber of times to all respondents and, as far as possible,
also, within a respondent, an equal number of times.
Respondents were also asked four questions regarding
their own and their patients’ preferences and motivations.
Additionally, respondents were asked to indicate, on a scale
ranging from one to seven, whether they agreed or dis-
agreed (1 = strongly disagree, 7 = strongly agree) with a
series of statements regarding oral versus LAI medications,
and one LAI medication versus another. Scores of 5, 6 and
7 were combined together to give an overall definition of
‘agree’ where 5 was ‘somewhat agree’, 6 ‘agree’ and 7
‘strongly agree’.
Analyses
Analyses were divided broadly into attitudes regarding
oral versus long-acting medication, and regarding one
Figure 1 Choice-based conjoint exercise – oral versus long-acting choice task.
Table 1 Characteristics of antipsychotic treatment (oral versus LAI attributes)
Attribute Level Utility scores
Formulation Buttock muscle injection (gluteal) +73.2
Deltoid muscle injection 0
Level of fluctuation of active compound in the blood plasma Low 0
Medium +43.4
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Table 2 Characteristics of antipsychotic treatment




and healthcare staff contact
with patient
Once per 3 weeks +32.4
Once per 4 weeks +30.0
Once per 2 weeks 0




Weight gain of more than
7% of body mass
+102.6











Risk of embarrassment and




Routes of administration Buttock muscle (gluteal) +49.0
Deltoid muscle +45.4
Ventro gluteal 0
Table 3 Utility scores split by patient type
Attribute Level
Side effects Sedation
Sexual side effects (prolactin)
Weight gain of more than 7% of bo
mass
Extrapyramidal side effect
Metabolic side effects (diabetes,
hypercholesterolaemia, dyslipidaemi
Tardive dyskinesia




Risk of embarrassment and potential
harm to therapeutic relationship
Low risk
High risk
Routes of administration Buttock muscle (gluteal)
Deltoid muscle
Ventro gluteal
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One thousand seven hundred HCPs were approached
to participate in this study; a total of 891 HCPs
responded and completed the survey (a 52% response
rate). The survey sample included physicians/specialists
(78%) and nurses (22%). All physicians were psychiatrists
or neuropsychiatrists. Respondents were from The
Netherlands (n = 109), Belgium (n = 97), Germany (n =
182), Italy (n = 187), the UK (n = 83), France (n = 132),
and the Nordic countries (n = 101). Among the partici-
pating HCPs, 75% had at least 8 years’ experience in
psychiatry; 40% were based in a psychiatric hospital,
19% worked in a psychiatric department of a general
hospital, 11% in private practice, 4% in a medical psy-
chological centre, and 26% in another environment.
Conjoint analysis
Oral versus LAI medication attributes
Antipsychotic attributes, levels and utility scores are
listed in Table 1. The utility scores indicate the relative
preference respondents have for different levels within
an attribute. When compared to oral formulations,
respondents had a greater preference for gluteal over




2 to 5 episodes


















Table 4 Attitudes towards choice of antipsychotics for patients with schizophrenia – mean scores
Means statements, oral versus LAI All The
Netherlands
Belgium Germany Italy UK France Nordic
countries
N = 891 n = 109 n = 97 n = 182 n = 187 n = 83 n = 132 n = 101
1. If a patient is on a LAI antipsychotic and did not appear
at the administration appointment as prescribed I can act
upon it
5.4 5.6 5.1 5.6 5.8 5.6 4.6 5.7
2. If a patient is on oral antipsychotics, it is impossible to
ascertain whether the patient has been taking an
antipsychotic or not
4.3 4.4 4.9 3.3 4.7 4.1 4.5 4.2
3. Because of adherence advantages of LAIs, a lower rate of
relapse can be ensured
5.5 5.4 5.5 5.7 5.6 5.2 5.5 5.2
4. The best way of managing non-adherence with
antipsychotics (due to poor insight) is with LAIs
5.2 5.1 5.2 5.4 5.4 5.2 4.8 5.0
5. Administration of a LAI antipsychotic in the deltoid
muscle as opposed to the buttocks is a respectful way of
administering antipsychotics
4.6 4.7 4.6 4.4 4.4 5.2 4.7 5.0
6. The ability to administer a LAI antipsychotic in the
deltoid muscle instead of the gluteal muscle will lead to an
increase in the use of LAI antipsychotic medication
4.2 4.1 4.3 4.0 4.1 4.4 4.2 4.7
7. Current oral antipsychotics can get many patients well,
but LAI atypical antipsychotics will keep the patients well
4.6 4.7 5.0 3.8 5.0 4.8 5.0 4.5
Respondents (Base: total n = 891) were asked to indicate, on a scale ranging from one to seven, whether they agreed or disagreed (1 = strongly disagree,
7 = strongly agree) with statements comparing long-acting medication with oral medication (question numbers 1–4 and 7) and statements comparing deltoid
administration with oral administration (question numbers 5 and 6).
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nurses ascribe to gluteal over deltoid formulation. A low
fluctuation of active compound in the plasma and the
frequency of regular contact with the patient were also
identified as important attributes for antipsychotic
treatment.LAI versus LAI attributes
When considering LAI antipsychotic use, choice utilities
revealed that side effects, pain at administration site,
embarrassment and site of administration (gluteal versus
deltoid) were all important factors (Table 2). Tardive
dyskinesia was ranked as the most undesirable side ef-
fect, followed by metabolic issues (+42.3), extrapyram-
idal symptoms (+79.1), weight gain (+102.6), sexual side
effects (+107.2) and sedation (+200.6). When considering
pain at injection site, there was little difference in
preference for no or mild pain at injection site (+158.8
versus +158.7). Preference data predicted that no/mild ad-
ministration site pain, minimal risk of embarrassment/
damage to the therapeutic relationship and some sedation
but no other side effects were features of an ideal LAI.
Utility scores were also analysed by patient type
(Table 3); this analysis revealed that side effects, pain at
administration site, embarrassment and site of adminis-
tration (gluteal versus deltoid) were important factors
for all patients, regardless of patient type. There is a
slight preference for injecting in the buttock, except forpatients who have experienced two to five episodes then
the deltoid muscle is slightly preferred.
Analysis of results indicate that the preference for LAI
antipsychotics were stronger for more chronic patients;
40% of the participating HCPs preferred LAI antipsychotics
to oral treatment for patients experiencing a first episode
of schizophrenia, 90% of respondents preferred LAI
antipsychotics to oral medication for chronic patients with
two to five episodes, and 96% preferred LAI antipsychotics
to oral medication for patients with ≥6 episodes.
Relative importance for LAI characteristics: analysis of
attitudes and opinions
In this survey, attitudes towards LAI antipsychotics
compared with orals were generally positive (Table 4). In
particular, statements gaining the most agreement were
that LAI antipsychotics allow intervention to address
non-adherence (83% agreed), adherence advantages of
LAI antipsychotics ensure a lower rate of relapse (87%
agreed), and that LAI antipsychotics provide the best way
to manage non-adherence due to poor insight (80% agreed).
Sixty-one per cent of respondents agreed that deltoid ad-
ministration may be a more respectful way of administering
antipsychotics than gluteal administration. This statement
was most strongly supported by HCPs in the UK (Table 4).
Evaluation of responses to statements regarding oral
versus LAI medications showed that 47% of respondents
would be more likely to choose an LAI antipsychotic
than an oral formulation, if the choice of a deltoid
Figure 2 If a long-acting antipsychotic injection was available in the deltoid muscle, how would that influence your choice to
prescribe a long-acting injection compared to oral medication?
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site were available (Figure 2). This response varied slightly
according to country, with The Netherlands and the Nor-
dic countries showing the most positive response (53%),
and the UK showing the least positive response (34%).
Overall, almost one third of respondents thought that
their patients would be more easily motivated to accept
LAI antipsychotics in preference to oral antipsychotics if
the medication could be administered in the deltoid
muscle (Figure 3). Given the choice of a deltoid or a glu-
teal administration site, 54% of respondents preferred del-
toid to gluteal administration, compared with 14% who
would prefer the gluteal option (Figure 4). Furthermore,
60% of respondents believed their patients would accept
deltoid administration of LAI antipsychotic in preference
to gluteal administration (Figure 5). This varied somewhat
by country, with 73% of those in The Netherlands and
UK believing that their patients would prefer deltoid,
compared with 43% in Italy.
Sixty-seven per cent of respondents agreed that LAI
antipsychotic administration in the deltoid muscle in-
stead of the gluteal muscle decreases the social embar-
rassment involved. Overall, respondents considered that
having the choice between gluteal and deltoid LAI anti-
psychotic administration sites was important (Table 5);
86% of respondents considered that having a choice be-
tween intramuscular (IM) administration in the deltoid
or gluteal muscles was an advantage over not having this
choice (where not having this choice is no IM adminis-
tration into the deltoid muscle).
Overall, respondents did not agree with statements
regarding safety of one method of administration over the
other (Table 5). The statements that respondents disagreed
with were ‘administration in the deltoid muscle instead of
the gluteal muscle was safer for the administrator as the
patient was less likely to hit out during injection’ and ‘ad-
ministration in the gluteal muscle is safer compared withadministration in the deltoid muscle because nurses only
have experience with administration in the gluteal muscle’.
Discussion
The objectives of this survey were to understand factors
driving LAI use as well as attitudes and preferences for dif-
ferent administration sites, both in comparison with oral
medication and with other LAI medication. Conjoint ana-
lysis was employed to examine trade-offs between specific
antipsychotic characteristics including formulation, fre-
quency of administration and route of administration to
understand attitudes and preferences for different adminis-
tration sites. Results of the survey provide insight to the
attitudes of a large number of HCPs across Europe on the
availability and use of LAI versus oral medication for the
treatment of patients with schizophrenia. However, it is im-
portant to note that the HCPs surveyed did not evaluate
antipsychotic treatment options directly. Rather, the con-
joint analysis method employed calculates utilities based on
respondents’ answers to specific trade-off questions. These
utilities are then used to predict which option most closely
suits each HCP’s individual preferences.
Conjoint analysis highlighted that side effects, pain at
administration site, embarrassment and site of adminis-
tration were all considered to be important factors by
this group of HCPs when choosing between anti-
psychotic treatments, for both first episode and chronic
schizophrenia patients. The majority of HCPs surveyed
(96%) preferred LAI medications to oral treatment for
patients with chronic schizophrenia whereas 40% pre-
ferred this type of medication for first episode patients.
Further analysis indicates that there is a slight preference
for injecting in the buttock, except for patients who have
experienced two to five episodes, then the deltoid
muscle is slightly preferred. Preference for oral formula-
tion over LAI in first-episode patients is aligned with
previously reported findings that, despite the adherence
Figure 3 If a long-acting antipsychotic could be injected in the deltoid muscle, then, compared to oral medication, my patients would be.
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amongst psychiatrists to use these medications for first-
line treatment [31,32].
Attitudes towards LAI antipsychotics compared with
oral medications were generally positive; most HCPs
surveyed agreed that LAI antipsychotics allowed inter-
vention to address non-adherence (83% agreed) and
provided the best way to manage non-adherence due to
poor insight (87% agreed). Non-adherence to anti-
psychotic medication is common in patients with schizo-
phrenia, with at least one third of patients having
problems with adherence in any given year and the ma-
jority of patients experiencing difficulties with medica-
tion adherence at some time during the course of their
illness [41]. Reduced adherence is associated with
increased risk of relapse [6], increased hospitalization [6]
and a higher economic burden [14-16]. Intramuscular
LAI antipsychotics can improve medication adherence
compared with daily oral medication [18,32] due to their
inherent sustained delivery of medication as well as the
regular treatment monitoring by healthcare professionals.
There is growing evidence that patients who remain on
antipsychotic treatment experience additional benefits be-
yond symptomatic control, such as improvements in
health-related quality of life [42]. This highlights the im-
portance of educating patients and relatives on the
consequences of partial and non-adherence and raising
awareness of the treatment options available to overcome
poor adherence to medication in psychosis. Furthermore,
it is important to ensure HCPs receive up-to-date infor-
mation on LAI and depot medication so as to promote a
more positive attitude [43,44].
Despite their potential clinical benefits, a systematic
review of attitudes of staff and patients noted that LAI
antipsychotics are often only used as a last resort for the
most stigmatized individuals [37]. Furthermore, a cross-
sectional survey of patients, relatives and psychiatristsrevealed that only 21% of patients without previous ex-
perience of injectable antipsychotics are informed of the
option and only 9% are recommended to switch to an
LAI antipsychotic by their psychiatrists [32]. In the sur-
vey reported here, HCPs considered side effects, pain
associated with injection, embarrassment and site of ad-
ministration were potential barriers to the use of LAI
antipsychotics in both early stage and chronic patients
with schizophrenia. No or mild administration site pain,
minimal risk of embarrassment/damage to the thera-
peutic relationship and some sedation but no other side
effects were ideal features of LAI antipsychotics identi-
fied by HCPs in the survey.
This survey of physicians and nurses from around
Europe also revealed that having the choice of a deltoid
as well as a gluteal administration site is perceived as
beneficial over not having the choice of a deltoid admin-
istration. Respondents believed that the deltoid site may
improve acceptance of LAI antipsychotics and be pre-
ferred by their patients. Two thirds of respondents
agreed that deltoid administration may reduce social
embarrassment associated with LAI antipsychotics. Most
respondents (61%) said they believed that administration
of LAI antipsychotics into the deltoid muscle as opposed
to the gluteal muscle might be considered more respect-
ful to the patient. A recent 25-week study, conducted in
Europe and the USA, noted that approximately half of
patients preferred deltoid to gluteal muscle injections
with the most common reasons for this preference being
that it was easier, less embarrassing, faster and more
convenient than injection in the gluteal muscle [39]. The
current survey suggests that the relevance of a deltoid
administration site for patient preference and for the
embarrassment associated with gluteal administration
may vary by country and culture.
It is remarkable that the perception of the deltoid admin-
istration seemed to improve as the survey progressed: in
Figure 4 If a long-acting injection of antipsychotics was available in the deltoid muscle as well as in the buttocks (gluteal), how would
this influence your prescription of long-acting antipsychotics?
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negative utility, while in the reactions to the statements
distilled from the literature it was received quite positively.
Potentially this reflects a relative unfamiliarity with this
mode of administration in practice at the time of the
survey.
The availability of LAI antipsychotic deltoid adminis-
tration, such as for RLAI and paliperidone palmitate,
increases choice in LAI antipsychotic administration,
allowing patients and HCPs the opportunity to select an
administration site which may be perceived as more re-
spectful and less socially embarrassing. The efficacy of
RLAI has been demonstrated in a number of studies
[21,45-47] and the deltoid and gluteal injections of RLAI
are interchangeable in terms of drug exposure [27].
Maintenance doses of paliperidone palmitate are
administered once-monthly, in either the deltoid or glu-
teal muscle. The efficacy of paliperidone palmitate for
adult patients with schizophrenia has been demonstrated
in several studies ranging from 9 to 52 weeks [48-51].Figure 5 Compared to an injection in the buttock muscle, my patientConclusions
The purpose of this study was to understand factors driving
LAI antipsychotic use as well as attitudes and preferences for
different administration sites, both in comparison with oral
medication and with other LAI medication as previous studies
have suggested that attitudes amongst HCPs may influence
medication choices offered to patients [36]. The results of this
survey highlight that the majority of HCPs would consider
LAI antipsychotics in preference to oral medication for
patients with chronic schizophrenia, whilst 40% of those
surveyed would select this type of medication for first-episode
patients. Attitudes towards LAI antipsychotics compared with
orals were generally positive; the ability to identify and address
non-adherence were considered key features of LAI anti-
psychotic compared with oral medication. Dominant elements
in antipsychotic choice were low sedation but no tardive dys-
kinesia, no or mild pain at injection and low risk of embarrass-
ment or impact upon therapeutic alliance. The choice of a
deltoid as well as a gluteal LAI antipsychotic administra-
tion site was perceived as beneficial over not having thes would accept an injection in the deltoid muscle.
Table 5 Choices regarding LAI administration
Means statements, oral versus LAI All The
Netherlands
Belgium Germany Italy UK France Nordic
countries
N = 891 n = 109 n = 97 n = 182 n = 187 n = 83 n = 132 n = 101
1. Compared to administration in the gluteal muscle,
administration in the deltoid muscle will help safeguard
your therapeutic relationship with the patient by showing
more respect for his or her dignity
4.4 4.6 4.3 4.1 4.2 4.9 4.4 4.8
2. IM administration in the deltoid muscle instead of the
gluteal muscle decreases social embarrassment during
administration
4.8 5.3 4.9 4.4 4.7 5.3 4.4 5.1
3. Administration in the gluteal muscle might incite some
patients to make sexual connotations
3.9 4.3 3.3 3.6 4.1 4.1 4.0 4.2
4. IM administration in the deltoid muscle instead of the
gluteal muscle is safer for the administrator as the patient
is less likely to hit out during injection
3.2 3.2 3.1 2.7 3.5 3.3 3.1 3.8
5. Administration in the gluteal muscle might increase
paranoia in some patients because they cannot see what is
going on behind their back
4.0 4.3 4.1 3.6 4.1 3.9 4.1 4.3
6. Having a choice between IM administration in the
deltoid or gluteal muscle is an advantage over not having
this choice
5.6 6.0 5.4 5.1 5.7 5.8 5.6 5.9
7. Administration in the gluteal muscle is safer compared
with administration in the deltoid muscle because nurses
only have experience with administration in the gluteal
muscle
3.4 3.8 3.1 3.6 3.0 4.0 3.4 3.5
Respondents (Base: total n = 891) were asked to indicate, on a scale ranging from one to seven, whether they agreed or disagreed (1 = strongly disagree,
7 = strongly agree) with statements comparing long-acting deltoid administration with gluteal administration (question numbers 1–7).
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deltoid administration therefore offers additional oppor-
tunity in the mode of LAI antipsychotic administration.
Limitations
Our results must be considered in view of the limitations
of the study. Conjoint analysis does not directly evaluate
antipsychotic treatment options but calculates utilities to
predict which treatment options most closely suits HCPs
preferences. It also assumes that utilities for individual
treatment characteristics are additive and does not per-
mit exploration of interaction effects. In addition, as
with all questionnaires, the description of the attributes
may influence respondents’ judgment. However, conjoint
analysis can also help overcome the known difficulties in
communicating complex risk information. One of the
main advantages of choice-based conjoint analysis is that
it is interactive, allowing the investigator to evaluate a
large number of attributes without information overload
or respondent fatigue. This is particularly important as
often the majority of complex medical decisions involve
multiple trade-offs. In addition, choice-based conjoint
analysis constructs utilities based on trade-offs between
specific treatment characteristics. This minimizes the biases
associated with the context in which choices are presented.
Additionally, treatment characteristics can be presented in
random order, thus eliminating potential ordering effects.
Furthermore, by asking respondents to consider specifictreatment advantages and disadvantages, it makes trade-
offs between competing options explicit which has been
shown to improve the quality of decision-making.
The nature of the recruitment process does create a certain
selection bias, as only contacted physicians who were willing
to complete the online questions were included. Even though
they were randomly selected from a much larger list, a purely
random sample could have been more appropriate. This was
not performed to ensure adequate numbers of respondents.
However, the majority of participants had extensive clinical
experience (≥8 years), treating patients in a variety of settings
including specialist psychiatric hospitals, general hospitals
and medical psychological centres, and represented countries
across Europe. While interpreting the results of such a
discrete choice experiment, the effect of prior knowledge on
the decision problem should be taken into account. In this
survey, clinical experience with LAI antipsychotics may influ-
ence physician and nurse attitudes regarding this type of
administration routes compared with those respondents
without extensive experience of long-acting medication. Fur-
thermore, it is important to acknowledge that the questions
covered in this choice-based survey required participants to
choose between bundles of predefined attributes; the limita-
tion of this design is that such stated opinions may not re-
flect actual opinion or predict actual behaviour.
The current survey involved multidisciplinary HCPs
(physicians/specialists: 78%; nurses: 22%). Attitudes and
preferences for physicians versus nurses or psychiatrists
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http://www.biomedcentral.com/1471-244X/13/58versus non-psychiatrists were not analysed here. Although
such analysis could provide insight into differences be-
tween HCPs, this was beyond the scope of this study. Fur-
thermore, the inclusion of both psychiatrists and nurses
reflects the situation in clinical practice with multidiscip-
linary teams involved in developing treatment plans.
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